Phase 1 N=24 OTR Tablet 10 mg Fasted-state Bioequivalence Study
Chronic Pain
Primary: Cmax of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State — 11.617; 10.564 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers
Asthma
Primary: Percent Predicted FEV1 — 58.6; 56.3 % of predicted value — p=0.745
N/A N=13 Video Based Mindfulness Based Stress Reduction
Parkinson's Disease
Primary: Salivary Cortisol Levels (Pre- and Post-) Mindfulness-Based Stress Reduction Program — -33.1 Concentration (ng/mL)
N/A N=17 Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy
Breast Cancer
Primary: Subharmonic Aided Pressure Estimation (SHAPE) After Treatment for Complete Responders — 3.23; 1.67 dB
Phase 3 N=743 Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
Neovascular Age-Related Macular Degeneration · Choroidal Neovascularization
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye — 6.9; 7.6 letters — p=<0.0001
N/A N=13 Hydrogel Injection to Assist Endoscopic Submucosal Dissection
Submucosal Tumor of Gastrointestinal Tract
Primary: Number of Patients With Postpolypectomy Electrocoagulation Syndrome — 0 Participants
Phase 3 N=1,082 Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
Neovascular Age-Related Macular Degeneration · Choroidal Neovascularization
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye — 5.9; 6.4; 7.0 letters — p=0.0003
N/A N=51 Effects of Combined rTMS and Treadmill Training in People With Parkinson's Disease
Parkinson's Disease
Primary: Fastest Walking Speed — 149.5; 153.1; 156.1; 164.3 cm/s
N/A N=14 Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
HIV
Primary: Concentration of Elvitegravir in Cerebrospinal Fluid at Baseline — 4.3; 2.72 ng/mL
N/A N=201 Analysis of Sweat Secretion and Body Dehydration Monitoring
Dehydration
Primary: Number of Measurements Grouped by Level or Error — 48; 48; 49; 50 Number of measurements
N/A N=3,000 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery
Major Abdominal Surgery
Primary: Number of Participants With Disability-free Survival — 1232; 1223 Participants
Phase 3 N=219 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Anklyosing Spondylitis
Primary: Percentage of Participants Achieving ASAS 20 (SpondyloArthritis International Society Criteria) Response at Week 16 — 41.1; 61.1; 28.4 percentage of participants…
Phase 2 N=13 FET-PET for Evaluation of Response of Recurrent GBM to Avastin
Glioblastoma Multiforme · GBM
Primary: Progression-free Survival — 158.25 days
Phase 1 N=48 Staccato Loxapine Thorough QT/QTc Study
Thorough QT/QTc Study
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.418 mseconds
N/A N=62 Clinical Trial to Assess the Effectiveness of Applying Dry Local Heat and/ or High Tourniquet Pressure for Venipuncture.
Venipuncture · Healthy Adult
Primary: Number of Participants With Successful Venous Catheterization at the First Attempt — 21; 18; 19; 28 Participants — p=0.001